Primary Biliary Cholangitis is a rare, progressive, chronic autoimmune disease of the liver in which the small bile ducts are gradually destroyed, causing bile and other toxins to build up in the liver (known as cholestasis). Further damage can lead to scarring, fibrosis and eventually cirrhosis of the liver. Ursodeoxycholic acid (UDCA) and Intercept Pharma's Ocaliva are some of the FDA-approved drugs for primary biliary cholangitis.
The company we are profiling today is Genfit S.A. (GNFT) which is also developing a therapeutic for primary biliary cholangitis.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com